Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed by initial debulking surgery.
Epithelial Ovarian Cancer
DRUG: Intraperitoneal (IP) Cisplatin
Safety and Dose Tolerance, Day 1 of each cycle and assessed every 3 months in follow-up (if applicable)
Time to progression, Day 1 of cycle 1 & 2 and every 3 months in follow-up until progression noted
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed by initial debulking surgery.